This study is in progress, not accepting new patients

Tailored Drug Titration Using Artificial Intelligence

a study on High Blood Pressure

Summary

Eligibility
for people ages 21-80 (full criteria)
Location
at San Francisco, California
Dates
study started
estimated completion
Principal Investigator
by Liviu Klein, MD
Photo of Liviu Klein
Liviu Klein

Description

Summary

The purpose of the ARTERY Outcomes study is to compare optima-for-blood pressure (optima4BP), a clinical decision support system for hypertension (HTN) treatment optimization to standard of care in patients with essential HTN.

Official Title

ARTERY Outcomes: Tailored Drug Titration Through Artificial Intelligence - an Interventional Study

Details

Nearly 34 million Americans have their blood pressure (BP) uncontrolled. Hypertension (HTN) claims 1000 deaths every day. Despite medication and life-style management, the cost of HTN associated hospitalizations had escalated to $113 billion in 2016, or 15% of all hospital costs, with >135 million Emergency Department (ED) visits. Uncontrolled HTN for even a few weeks is associated with increased risk for acute cardiovascular (CVD) events [stroke, heart failure (HF), myocardial infarction (MI)] and death. Medication treatment optimization to BP goal reduces the incidence of stroke by 35-40%, HF by up to 64%, and MI by 15-25%. optima-for-blood pressure [optima4BP] transforms the episodic and reactive nature of uncontrolled HTN pharmacological treatment management into a process that is continuous, proactive, and personalized. The innovation simulates the established clinical reasoning treatment decision process undertaken during a patient's visit.

Keywords

Hypertension optima4BP

Eligibility

You can join if…

Open to people ages 21-80

  • Two or more blood pressure (BP) readings of ≥ 140/90 mmHg during UCSF primary care or cardiology office visits within the last 12 months
  • Therapy with medications from at least 1 anti-HTN pharmacological agents at the time of the last office visit
  • At least minimally "tech-savvy" defined as Ownership of a compatible smartphone and Ability to access the internet
  • Active Electronic Health Record MyChart account

You CAN'T join if...

  • Home anti-HTN medication therapy doesn't match the electronic health record medication list
  • Anti-HTN medication therapy changed within 30 days prior to enrollment
  • Inability to operate a BP cuff
  • Incompatible smartphone device (Galaxy S5 Android 5.0)
  • Less than minimally "tech-savvy" defined as Inability to use the Internet
  • Non-compliance with medical follow-up (>3 "no shows" in the previous 12 months)
  • Planned coronary revascularization in the next 12 months
  • Myocardial infarction, coronary revascularization, stroke, cardiac or aortic surgery in the previous 90 days
  • GFR < 30 (CKD stage IV/ V)
  • Treating physician rules out the patient due to superseding health management concerns
  • Treating physician rules out the patient due to other concerns

Location

  • University of California San Francisco
    San Francisco California 94143 United States

Lead Scientist at UCSF

  • Liviu Klein, MD
    Associate Professor, Medicine. Authored (or co-authored) 78 research publications. Research interests: Ventricular assist devices · Extracorporeal life support · Cardiac resynchronization therapy · Implantable hemodynamics monitors · Implantable cardioverter defibrillators · Heart transplantation · Wearable sensors · Sudden death.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Optima Integrated Health
ID
NCT04223934
Study Type
Interventional
Last Updated